S
QNCX icon

SignatureFD’s Quince Therapeutics QNCX Stock Holding History

SignatureFD’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Hold
0
– -$1K – 3288
2021
Q4 		– Sell
-3
Closed -$18.3K – 2976
2021
Q3 		$59K Hold
3
– – ﹤0.01% 1231
2021
Q2 		$34K Hold
3
– – ﹤0.01% 1465
2021
Q1 		$22K Hold
3
– – ﹤0.01% 1542
2020
Q4 		$14K Sell
3
-3
-50% -$26.6K ﹤0.01% 1579
2020
Q3 		$55K Hold
6
– – ﹤0.01% 944
2020
Q2 		$52K Buy
+6
New +$55K ﹤0.01% 935

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SignatureFD's QNCX Position: Q1 2022 in Review

SignatureFD held its Quince Therapeutics (QNCX) position steady in Q1 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3288.

SignatureFD first reported a position in QNCX in Q2 2020 and has held it in 6 quarters since. The position peaked at $59K in Q3 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

  • SignatureFD held 0 shares of Quince Therapeutics worth $0 as of Q1 2022.
  • SignatureFD left its Quince Therapeutics share count unchanged in Q1 2022.
  • Quince Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2022, its #3288 holding.
  • SignatureFD first reported a position in Quince Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • SignatureFD's Quince Therapeutics position peaked at $59K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on SignatureFD's 13F filing for Q1 2022, filed 2 May 2022.